The FGF13‐Caveolin‐1 Axis: A Key Player in the Pathogenesis of Doxorubicin‐ and D‐Galactose‐Induced Premature Cardiac Aging
Advanced Science · 2025
DOI: 10.1002/advs.202501055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Enzhao Shen und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, P. R. China. Hauptthemen laut MEDLINE: Doxorubicin, Fibroblast Growth Factors, Galactose, Caveolin 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ningbo City Public Welfare Research Plan Project.
Abstract (Originalsprache)
Delaying senescence of cardiomyocytes has garnered widespread attention as a potential target for preventing cardiovascular diseases (CVDs). FGF13 (Fibroblast growth factor 13) has been implicated in various pathophysiological processes. However, its role in premature myocardial aging and cardiomyocyte senescence remains unknown. Adeno‐associated virus 9 (AAV9) vectors expressing FGF13 and cardiac‐specific Fgf13 knockout (Fgf13KO) mice are utilized to reveal that FGF13 overexpression and deficiency exacerbated and alleviated Doxorubicin/D‐galactose‐induced myocardial aging characteristics and functional impairment, respectively. Transcriptomics are employed to identify an association between FGF13 and Caveolin‐1 (Cav1). Mechanistic studies indicated that FGF13 regulated the Cav1 promoter activity and expression through the p38/MAPK pathway and nuclear translocation of p65, as well as the binding level of PTRF to Cav1 to mediate cardiomyocyte senescence. Furthermore, Cav1 overexpression in murine hearts reversed the alleviatory effects of FGF13 deficiency on the Doxorubicin/D‐galactose‐induced myocardial aging phenotype and dysfunction. This study has demonstrated that FGF13 regulated the Cav1‐p53‐p21 axis to augment cardiomyocyte senescence and thereby exacerbated cardiac premature aging and suggests that FGF13 knockdown may be a promising approach to combat CVDs in response to aging and chemotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, P. R. China.
- College of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju, 61186, Republic of Korea.
- Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, P. R China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, P. R. China.
- Ningbo Key Laboratory of Skin Science, Ningbo College of Health Sciences, Ningbo, 315000, P. R. China.
ORCID-Profile: Weitao Cong
Förderung
- National Natural Science Foundation of China
- Ningbo City Public Welfare Research Plan Project
Zitieren
APA
Shen, E., Wu, Y., Ye, W., Li, S., Zhu, J., Jiang, M., Hu, Z., Cao, G., Yi, X., Li, F., Tang, Z., Li, X., Lee, K. Y., Jin, L., Wang, X., & Cong, W. (2025). The FGF13‐Caveolin‐1 Axis: A Key Player in the Pathogenesis of Doxorubicin‐ and D‐Galactose‐Induced Premature Cardiac Aging. Advanced Science. https://doi.org/10.1002/advs.202501055
Vancouver
Shen E, Wu Y, Ye W, Li S, Zhu J, Jiang M, et al. The FGF13‐Caveolin‐1 Axis: A Key Player in the Pathogenesis of Doxorubicin‐ and D‐Galactose‐Induced Premature Cardiac Aging. Advanced Science. 2025. doi:10.1002/advs.202501055
BibTeX
@article{Shen2025,
author = {Shen, Enzhao and Wu, Yuecheng and Ye, Weijian and Li, Sihang and Zhu, Junjie and Jiang, Meifan and Hu, Zhicheng and Cao, Gaoyong and Yi, Xiaojing and Li, Fan and Tang, Zhouhao and Li, Xiaokun and Lee, Kwang Youl and Jin, Litai and Wang, Xu and Cong, Weitao},
title = {The FGF13‐Caveolin‐1 Axis: A Key Player in the Pathogenesis of Doxorubicin‐ and D‐Galactose‐Induced Premature Cardiac Aging},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202501055}
}
EUVIMED